Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us 
About
Not Confirmed
Not Confirmed
01-03 May, 2026
Not Confirmed
Not Confirmed
03-07 May, 2026
AOCS Annual MeetingAOCS Annual Meeting
Not Confirmed
Not Confirmed
03-06 May, 2026
List your booth number for exhibitions, ask us 
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
AMWC Asia-TDAC
Not Confirmed
Contact SupplierAMWC Asia-TDAC
Industry Trade Show
Not Confirmed
01-03 May, 2026
Industry Trade Show
Not Confirmed
03-07 May, 2026
AOCS Annual MeetingAOCS Annual Meeting
Industry Trade Show
Not Confirmed
03-06 May, 2026
Digital content
NEWS #PharmaBuzz
15 Apr 2026
// EXPRESSPHARMA
https://www.expresspharma.in/aurigene-and-alveus-therapeutics-advance-collaboration-with-alv-200-candidate-nomination/
25 Feb 2026
// BIOSPACE
https://www.biospace.com/business/slate-alveus-raise-hefty-series-a-hauls-for-migraine-obesity-drugs
24 Feb 2026
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2026/02/24/3243418/0/en/Alveus-Therapeutics-Announces-Second-and-Final-Closing-of-Oversubscribed-Series-A-Bringing-Total-Financing-to-197-Million-to-Advance-Next-Generation-Therapies-for-Obesity-and-Metab.html
23 Jan 2026
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2026/01/23/3224643/0/en/Alveus-Therapeutics-Announces-FDA-Clearance-of-IND-and-First-Patient-Dosed-in-Phase-1b-Trial-of-ALV-100-for-Obesity.html
15 Jan 2026
// BUSINESSWIRE
https://www.businesswire.com/news/home/20260115622477/en/InterAx-and-Alveus-Announce-Strategic-Research-and-Licensing-Agreement-to-Develop-Differentiated-Therapeutic-Candidate-for-Metabolic-Disease
08 Jan 2026
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2026/01/08/3215272/0/en/Alveus-Therapeutics-Launches-with-160-Million-Series-A-Financing-to-Advance-Next-Generation-Therapies-for-Obesity-and-Metabolic-Diseases.html
Drugs in Development
Details:
The Series A financing for ALV-100, a protein targeting GIPR and GLP-1R, aims to advance obesity treatment.
Lead Product(s): ALV-100
Therapeutic Area: Nutrition and Weight Loss Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Protein
Sponsor: Jeito Capital | Novo Holdings | New Rhein Healthcare Investors | Andera Partners | Omega Funds | Sanofi Capital | Kurma Partners | Avego BioScience Capital
Deal Size: $197.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing February 24, 2026
Lead Product(s) : ALV-100
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Jeito Capital | Novo Holdings | New Rhein Healthcare Investors | Andera Partners | Omega Funds | Sanofi Capital | Kurma Partners | Avego BioScience Capital
Deal Size : $197.0 million
Deal Type : Series A Financing
Alveus Therapeutics Completes Series A Funding of $197M for Obesity Therapies
Details : The Series A financing for ALV-100, a protein targeting GIPR and GLP-1R, aims to advance obesity treatment.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Undisclosed
February 24, 2026
Details:
ALV-100 is a antibody-protein conjugate, which is currently being evaluated in Phase I clinical studies for the treatment of overweight.
Lead Product(s): ALV-100
Therapeutic Area: Nutrition and Weight Loss Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Antibody-protein Conjugate
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 10, 2026
Lead Product(s) : ALV-100
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ALV-100 is a antibody-protein conjugate, which is currently being evaluated in Phase I clinical studies for the treatment of overweight.
Product Name : Undisclosed
Product Type : Antibody-protein Conjugate
Upfront Cash : Inapplicable
February 10, 2026
Details:
ALV-100, a protein targeting GIPR and GLP-1R, shows promise in treating obesity.
Lead Product(s): ALV-100
Therapeutic Area: Nutrition and Weight Loss Brand Name: Undisclosed
Study Phase: IND EnablingProduct Type: Protein
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 23, 2026
Lead Product(s) : ALV-100
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : IND Enabling
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Alveus Therapeutics Clears FDA IND, Doses First Patient in ALV-100 Obesity Trial
Details : ALV-100, a protein targeting GIPR and GLP-1R, shows promise in treating obesity.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
January 23, 2026
Details:
The collaboration aims to develop innovative solutions for metabolic diseases.
Lead Product(s): Undisclosed
Therapeutic Area: Endocrinology Brand Name: Undisclosed
Study Phase: Discovery PlatformProduct Type: Miscellaneous
Recipient: InterAx Biotech
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration January 15, 2026
Lead Product(s) : Undisclosed
Therapeutic Area : Endocrinology
Highest Development Status : Discovery Platform
Recipient : InterAx Biotech
Deal Size : Undisclosed
Deal Type : Collaboration
InterAx, Alveus Partner to Develop Therapeutic Candidate for Metabolic Disease
Details : The collaboration aims to develop innovative solutions for metabolic diseases.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
January 15, 2026
Details:
The Series A financing for ALV-100, a protein targeting GIPR and GLP-1R, will advance research in obesity.
Lead Product(s): ALV-100
Therapeutic Area: Nutrition and Weight Loss Brand Name: Undisclosed
Study Phase: PreclinicalProduct Type: Protein
Sponsor: Rhein Healthcare Investors | Andera Partners | Omega Funds
Deal Size: $160.0 million Upfront Cash: $160.0 million
Deal Type: Series A Financing January 08, 2026
Lead Product(s) : ALV-100
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Rhein Healthcare Investors | Andera Partners | Omega Funds
Deal Size : $160.0 million
Deal Type : Series A Financing
Alveus Therapeutics Launches with $160M to Advance Next-Gen Therapies for Obesity
Details : The Series A financing for ALV-100, a protein targeting GIPR and GLP-1R, will advance research in obesity.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : $160.0 million
January 08, 2026
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]ABOUT THIS PAGE
Share 
